As an ovarian cancer survivor, here is an ASCO-related story that interested me:

ASCO: Antibody Shows Promise in Ovarian Cancer
By Charles Bankhead, Staff Writer, MedPage Today
Published: June 10, 2010
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine.

CHICAGO — Women with relapsed, platinum-sensitive epithelial ovarian cancer had a 70% overall response rate to treatment with a taxane plus an antifolate receptor antibody, data from a small clinical trial showed.

The phase II clinical trial evaluated responses in 44 ovarian cancer patients in their first relapse period, who received either farletuzumab as a single agent or in combination with carboplatin and a taxane. The total clinical benefit exceeded 90% when factoring in patients who had prolonged periods of stable disease, said Alan J. White, MD, of the Cancer Research and Treatment Center in San Antonio, Texas.

More than 20% of the women had a second platinum-free interval that exceeded the duration of the first, White reported here at the American Society of Clinical Oncology meeting. Having a platinum-free interval after first-line chemotherapy had no impact on the likelihood of response, he added.

“Compared to historical progress-free and platinum-free intervals, farletuzumab increases the overall response rate and the duration of second interval when combined with carboplatin and a taxane,” he said.

This article is extensive and detailed. Let’s jump ahead to the conclusion:

Previous studies have shown that the duration of platinum-free interval strongly influences response to therapy in ovarian cancer, said Hilary Calvert, MD, an invited discussant of White’s presentation. Calvert’s own assessment of the patient population suggested an overall response rate of less than 30%.

“You wouldn’t have expected anything like the response rate that was observed,” said Calvert, of University College London. “Second remissions normally are not longer than first remissions, so the observation that nine of these patients had a second response that was longer than the first one is highly significant.”

Sounds like more good news for a specific group of ovarian cancer patients who previously had little hope. Researchers keep chipping away, don’t they? Read the entire article, Antibody Shows Promise in Ovarian Cancer, on medpagetoday.com.

It is good to have my husband back home! He is tired and sore–but he really likes his job! Feel good and keep smiling! Pattie

Leave a Reply